$2.35
0.42% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US03589W1027
Symbol
ANNX

Annexon Inc Stock price

$2.35
-0.23 8.91% 1M
-0.76 24.44% 6M
-2.78 54.19% YTD
-3.26 58.11% 1Y
-3.27 58.19% 3Y
-21.59 90.18% 5Y
-15.41 86.77% 10Y
-15.41 86.77% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.01 0.42%
ISIN
US03589W1027
Symbol
ANNX
Industry

Key metrics

Basic
Market capitalization
$258.9m
Enterprise Value
$-4.8m
Net debt
positive
Cash
$263.7m
Shares outstanding
109.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.0
P/B
1.1
Financial Health
Equity Ratio
83.7%
Return on Equity
-47.2%
ROCE
-67.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-180.8m | $-237.9m
EBIT
$-182.9m | $-240.3m
Net Income
$-167.4m | $-162.6m
Free Cash Flow
$-139.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-40.2% | -56.6%
EBIT
-39.6% | -56.0%
Net Income
-38.6% | -17.6%
Free Cash Flow
-20.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-1.3
Short interest
11.9%
Employees
100
Rev per Employee
$0.0
Show more

Is Annexon Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Annexon Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Annexon Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Annexon Inc forecast:

Buy
93%
Hold
7%

Financial data from Annexon Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
26% 26%
-
- Research and Development Expense 147 147
43% 43%
-
-181 -181
40% 40%
-
- Depreciation and Amortization 2.15 2.15
0% 0%
-
EBIT (Operating Income) EBIT -183 -183
40% 40%
-
Net Profit -167 -167
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Annexon Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Annexon Inc Stock News

Neutral
GlobeNewsWire
4 days ago
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
Neutral
GlobeNewsWire
19 days ago
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation
Negative
Seeking Alpha
28 days ago
Annexon is a speculative Buy due to its late-stage Tanruprubart program targeting the high unmet need in Guillain-Barré Syndrome. Tanruprubart could become the standard of care for GBS if approved, given the lack of FDA-approved therapies and limited competition. The company faces near-term risks: delayed regulatory filings, high cash burn, and a likely need for additional funding within a year.
More Annexon Inc News

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in South San Francisco, CA.

Head office United States
CEO Douglas Love
Employees 100
Founded 2011
Website annexonbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today